What Researchers Did
Researchers evaluated the Carefusion Alaris PC infusion pump's suitability and performance under typical hyperbaric oxygen therapy conditions in their facility's multiplace chamber.
What They Found
They found the pumps posed no enhanced ignition risk and operated within manufacturer's specifications for flow rate and occlusion alarms. This was true at pressures up to 4.0 ATA and pressurization/depressurization rates up to 180 kPa/minute, without requiring modification or purging.
What This Means for Canadian Patients
For Canadian patients requiring hyperbaric oxygen therapy, this study suggests that the Carefusion Alaris PC infusion pump can be safely used to deliver medications. This ensures continuity of care and accurate medication delivery even in high-pressure environments.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada nor involved Canadian researchers or participants.
Study Limitations
The study's findings are specific to the tested pump model and the defined hyperbaric conditions, requiring adherence to strict operational guidelines.